Methods	Allocation:randomised-dose (cross-over trial). Blinding: single-blind. Duration:12 weeks.
Participants	Diagnosis:(DSM-III-R) chronic schizophrenia or schizoaffective disorder. N=20. Age: mean: 33.8 years (range=22-51). Gender: 7M-13F. Setting:19 outpatients and 1 inpatient. History:mean age at onset of psychosis was 22.7 years (range=15-32)
Interventions	Clozapine:dose 375 mg/day (range=75-800).N=10. Risperidone:dose 6.1 mg/day (range=1-10). N=10.
Outcomes	Leaving the study early: adverse effects. Global state: severity of illness sub scale of the CGI. Mental state: PANSS total score and positive and negative subscore. dverse effects: extrapyramidal (antiparkinson medication use), sedation, weight gain
Notes	No report of first arm outcomes (6 weeks).